<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> <z:e sem="disease" ids="C1290884" disease_type="Disease or Syndrome" abbrv="">inflammatory disorders</z:e> such as <z:e sem="disease" ids="C0021390" disease_type="Disease or Syndrome" abbrv="">inflammatory bowel diseases</z:e> (IBDs) affect bone metabolism and are frequently associated with the presence of <z:hpo ids='HP_0000938'>osteopenia</z:hpo>, <z:hpo ids='HP_0000939'>osteoporosis</z:hpo>, and increased risk of fractures </plain></SENT>
<SENT sid="1" pm="."><plain>Although several mechanisms may contribute to <z:hpo ids='HP_0000924'>skeletal abnormalities</z:hpo> in IBD patients, <z:mp ids='MP_0001845'>inflammation</z:mp> and <z:mp ids='MP_0002501'>inflammatory mediators</z:mp> such as TNF, IL-1Î², and IL-6 may be the most critical </plain></SENT>
<SENT sid="2" pm="."><plain>It is not clear whether the changes in bone metabolism leading to decreased mineral density are the result of decreased bone formation, <z:hpo ids='HP_0002797'>increased bone resorption</z:hpo>, or both, with varying results reported in experimental models of IBD and in pediatric and adult IBD patients </plain></SENT>
<SENT sid="3" pm="."><plain>New data, including our own, challenge the conventional views, and contributes to the unraveling of an increasingly complex network of interactions leading to the <z:mp ids='MP_0001845'>inflammation</z:mp>-associated bone loss </plain></SENT>
<SENT sid="4" pm="."><plain>Since nutritional interventions (dietary calcium and <z:chebi fb="27" ids="27300">vitamin D</z:chebi> supplementation) are of limited efficacy in IBD patients, understanding the pathophysiology of <z:hpo ids='HP_0000938'>osteopenia</z:hpo> and <z:hpo ids='HP_0000939'>osteoporosis</z:hpo> in <z:hpo ids='HP_0100280'>Crohn's disease</z:hpo> and <z:hpo ids='HP_0100279'>ulcerative colitis</z:hpo> is critical for the correct choice of available treatments or the development of new targeted therapies </plain></SENT>
<SENT sid="5" pm="."><plain>In this review, we discuss current concepts explaining the effects of <z:mp ids='MP_0001845'>inflammation</z:mp>, <z:mp ids='MP_0002501'>inflammatory mediators</z:mp> and their signaling effectors on calcium and phosphate homeostasis, osteoblast and osteoclast function, and the potential limitations of <z:chebi fb="27" ids="27300">vitamin D</z:chebi> used as an immunomodulator and anabolic hormone in IBD </plain></SENT>
</text></document>